Foundational Platform Thesis

We have developed proprietary synthesis methods for next generation 2D semiconductor and quantum materials with significant broad electronics upgrade implications.

We are leveraging these materials into semiconductor based biosensing systems with unique surface chemistry enabling a foundational shift in sensing.

Our platform enables continuous multi biomarker sensing beyond glucose using sweat, with future expansion into additional biofluids and microneedle systems.

Competing biosensing platforms require years and tens of millions of dollars to develop each new single biomarker capability. We already have 14+ lab validated biomarkers with a pathway toward a library of 100+ biomarkers within the same core platform architecture.

Foundational 2D Semiconductor Biosensing Platform

A foundational shift from single analyte sensors to scalable biological data systems

From glucose to 100 plus biomarkers unlocking continuous biological intelligence. Nano Performance Technologies has developed a 2D semiconductor sensing architecture validated through human and equine laboratory and field trials with outstanding results, designed to scale across biomarkers, products, and licensing markets without requiring redesign of the underlying platform. Initial product: a lab validated neuro hormonal wearable capable of detecting dopamine, norepinephrine, and cortisol in sweat, enabling real time human performance and wellness monitoring without FDA dependency. Demonstrated signal parity with gold standard HPLC laboratory methods without the laboratory infrastructure.

View the Raise Platform Overview

Validated Biomarkers

Substantial

Non Dilutive Funding

$1.5M

Raising Now

Late Seed SAFE

Pre Commercial Bridge

Supported by programs associated with DOD USAF DOE NSF and leading research institutions including Purdue MIT Stanford UC Berkeley and Rice

NPT is not building a single wearable product.

It is building the sensing architecture beneath a new generation of molecular devices.

Each validated biomarker expands the platform’s licensing surface area, product optionality, and future data value without requiring a new sensing system.

The Problem & Our Answer

Single analyte biosensing doesn’t scale

The current biosensing market is constrained by architectures that only detect one biomarker at a time. Every expansion requires rebuilding the system limiting speed, scalability, and economic viability.

The Old Constraint

One biomarker at a time

Existing biosensor companies are constrained to single target sensing systems like glucose monitors that must be entirely rebuilt for each new biological target. Expanding has historically required multi year development cycles and capital intensive redesigns costing tens of millions each. There is no path to platform scale from these architectures and have been highly capital inefficient.

The NPT Approach

A semiconductor architecture that compounds

NPT's 2D semiconductor platform supports 14 validated biomarkers today and the library expands without requiring device level redesign. Each new biomarker adds to the same foundation. The same architecture that detects neurotransmitters in sweat today will power clinical grade microneedle devices, licensing deals, and AI data infrastructure tomorrow. NPT's semiconductor materials introduce unique surface chemistry, enabling biological signal transduction with levels of sensitivity and reliability not achievable through conventional sensing approaches.

The Post Glucose Expansion

Glucose was the beginning. The real opportunity is scalable molecular panels.

Continuous glucose monitoring validated the behavior. The next phase is not another single analyte it is real time access to multiple biological systems through a single sensing architecture.

NPT’s 2D semiconductor platform directly transduces molecular signals into electrical output, enabling single, dual, and multi analyte detection without redesigning the underlying system.

Neurochemical state (acute)

Dopamine and norepinephrine enable real time insight into focus, cognitive load, and acute stress response. Dual marker detection has already been demonstrated in human testing.

Stress and recovery (chronic)

Cortisol enables continuous tracking of chronic stress, recovery cycles, and physiological baseline shifts completing the initial neuro-hormonal panel.

Metabolic systems

Glucose, lactate, and uric acid support real time tracking of energy utilization, exertion, and physiological load across performance environments.

Hormonal expansion

Future panels include estradiol and testosterone, expanding into endocrine health, performance optimization, and clinical monitoring applications.

Inflammation and disease

Cytokines (IL-6, TNF-alpha) and immune signaling markers enable continuous tracking of inflammation, disease progression, and therapeutic response.

Organ function and drug monitoring

Creatinine, electrolytes, and detectable drug compounds enable continuous monitoring of organ function, metabolism, and dosing dynamics.

Each biomarker can be deployed individually, in dual marker configurations, or as expanding panels with increasing data density, product capability, and licensing value at each step.

Applications span human performance, clinical devices, defense and space, and animal health including equine performance validated across both human and horse studies.

TellU Sense · 2D semiconductor platform → continuous biological data

The Product

From semiconductor platform to wearable reality

Validated in early human testing with real time multi biomarker detection outside controlled lab environments. TellU Sense is the first commercial expression of the platform an initial non invasive wedge into continuous molecular sensing, not the limit of the platform.

Multi-biomarker sensing 14 lab validated markers readable from a single wearable form factor
Surface chemistry advantage Unique 2D semiconductor surface chemistry enables signal transduction not achievable with conventional approaches
Real-time signal transduction Continuous biological monitoring not episodic snapshots
Expansion towards 100 plus Platform architecture scales the biomarker library without device redesign

Platform Expansion

An expanding biomarker library. No new hardware required.

Each new biomarker is deployed onto the same semiconductor platform. Devices are configured for specific use cases while the underlying library continues to expand and compound.

The first product is a lab-validated neuro-hormonal wearable a non invasive, sweat based system designed for human performance. It enables real time monitoring of dopamine, norepinephrine, and cortisol, providing insight into focus, acute stress, and chronic stress without requiring FDA approval for initial market entry.

This serves as the initial commercial wedge demonstrating multi biomarker capability in a real world product while the platform scales through larger licensing partnerships across wearables, diagnostics, and biosensing companies.

Example device configuration · 1–3 biomarkers per product · expanding platform library

Revenue Architecture

Four compounding platform layers

This is a platform system. Each layer reinforces the others expanding licensing surface area, product optionality, and long term data infrastructure.

Licensing Engine

Biomarker capabilities and platform access licensed to wearables, diagnostics, and biosensor companies. Structured deals target the $50M–$500M range as the library expands.

Primary

In-House Products

TellU Sense wearable systems sweat based market entry (non-FDA) with FDA microneedle optionality extending into clinical grade devices.

Near-term

Efficacy Standard Layer

Real time biological validation for pharmaceuticals and nutraceuticals. Positioned to become a new industry standard for efficacy measurement.

Emerging

AI Data Infrastructure

Live human biological data at scale high value datasets for AI models that cannot rely on synthetic data. A new category of data asset.

Long-term

The platform also extends beyond biosensing into next generation electronics and advanced semiconductor applications, with a growing portfolio of quantum materials IP. Biosensing is the initial market entry, not the ceiling.

Traction

The science is validated. The commercial pipeline is open.

Technology validated through funded research, lab testing, and early human trials.

Real-time neurotransmitter detection in human sweat

Demonstrated multi neurotransmitter detection in human subjects a milestone no competitor has reached with a scalable architecture. Live stress and focus neurotransmitter markers are now detectable through sweat with a growing validated biomarker library.

14 biomarkers validated across the platform

Lab validated across a growing biomarker library, each supported by the same underlying semiconductor architecture.

Institutional validation and non dilutive support

The underlying technology portfolio has been supported through programs associated with the United States Department of Defense, United States Air Force, United States Department of Energy, and the National Science Foundation, alongside research validation engagement with many leading Universities.

Corporate VC and strategic discussions active

Active discussions with multiple large corporate development and venture groups across semiconductor and medtech, including interest in leading a future Series A.

Market validation through I Corps discovery

Interviews across consumers, medtech diagnostics and research organizations confirmed strong pent up demand for multi analyte sensing for consumers and validated licensing as the preferred commercialization pathway.

$1M

First Paid Pilot Active Discussions

Pilot pathway potential ~$10M

Target Series A range $75M–$300M

Licensing deal range $50M–$500M

Investment bank discussions Active

Public market pathway (SPAC / IPO) Under evaluation for readiness and timing

Competitive Landscape

Comparable companies raised more with less

Biosensing has been constrained by iteration speed and cost. Legacy systems require years and significant capital to add a single biomarker, limiting scalability, data depth, and commercial potential. NPT enters with a platform that removes both constraints.

The bottleneck in biosensing is not detection. It is iteration speed and cost.

Key Constraint	Legacy Systems	NPT Platform
Time to add new biomarker	Years + high cost	Weeks

Competitors are structurally limited to narrow biomarker sets and cannot economically expand into large libraries or support broad licensing strategies. NPT’s platform uniquely enables both single and multi marker licensing across expanding biomarkers library.

Company	Architecture	Biomarkers	Scalable Platform	Semiconductor IP	Revenue Status	Capital Raised
NPT (us)	2D Semiconductor	14 validated	✓	✓	Pre-revenue	$1.5M (raising)
Typical Biosensor Co.	Biorecognition-limited	1–3	,	,	Pre-revenue	$10M–$100M+
Wearable Biosensor Co.	Single-analyte	1	,	,	Pre-revenue	$50M–$300M+
Diagnostics Platform	Enzyme-coupled electrochemical	3–5	Partial	,	Early revenue	$30M–$150M+

Competitive landscape is illustrative based on publicly available funding data from comparable biosensing ventures. Specific company names withheld.

The Raise

$1.5M Late Seed Bridge. Late Seed Pre Commercial.

This round funds execution, not discovery. Investors are entering at the earliest commercialization inflection before revenue visibility, before licensing scale, before product launch.

Stage

Late Seed

Pre Commercial

This round represents a late seed bridge into commercialization ahead of licensing conversion, product deployment, and revenue visibility. Execution from this stage is expected to materially re rate the company as it transitions into commercialization and licensing scale.

Amount

$1.5M

Late Seed Bridge

This round is designed to unlock a significant re-pricing event, positioning the company for a Series A in the $75M–$300M range.

First ~$1M paid pilot execution
Product deployment
Clinical positioning
Conversion into larger licensing deals

Entry Point

Now

Investors are entering before: revenue visibility licensing scale product launch. This is one of the last entry points before commercial launch and the associated valuation re-pricing.

Technology is de-risked
Platform is built
Human trials complete
Commercial demand emerging

Series A Re rating Roadmap

Series A

$75M–$300M Target Range

Already in discussions with multiple corporate VC and corporate development groups across semiconductor and medtech. Active dialogue with investment banks and SPAC sponsors as part of a long-term capital markets strategy.

Investor Fit

This is a deep tech investment.

Be clear-eyed about what this is and what it isn't.

This is for you if

You believe 2D semiconductor based biosensing is the future

You are a patient, thesis driven investor comfortable with pre revenue deep tech. You understand platform value, IP moats, and the upside of entering before commercial scale. You want to be in before the repricing.

This is not for you if

You need de-risked SaaS metrics today

If you require current revenue, proven commercial scale, or near term liquidity, this is not the right opportunity. We are pre revenue and early in commercialization. The upside is real but it requires conviction at this stage.

Team

Deep science. Commercialization focus.

This is not an abstract research effort. NPT combines Purdue grade technical depth with capital markets and strategic execution expertise.

Founder

Capital Markets & Deep Tech Commercialization

Capital markets and deep tech commercialization background, with experience in deal origination, partnerships, and strategic execution in advanced technologies.

Scientific Leadership

Purdue-Based Expertise

Multi award winning Purdue based expertise in biosensing, 2D materials, and semiconductor systems. Directly responsible for the $4M+ in federal non dilutive funding and the 14-biomarker validated platform.

Translational Expertise

Clinical & Regulatory Experience

PhD-level biosensor scientist with direct experience advancing continuous monitoring systems through clinical development and regulatory pathways, including major contributions to widely deployed large commercial biosensor platforms.

A combination of deep technical capability, real world biosensor deployment experience, and dynamic corporate vision with commercialization focus.